Lou Staudt and Shiv Grewal Named NIH Distinguished Investigators
NIH Director Dr. Francis Collins named Drs. Louis M. Staudt and Shiv Grewal NIH Distinguished Investigators. This title is conferred upon preeminent researchers whose career accomplishments are considered exceptional. Fewer than 3 percent of NIH researchers bear the title, which requires peer and NIH director review and approval.
Dr. Staudt, deputy chief of the Metabolism Branch in NCI's Center for Cancer Research (CCR), has led a major effort to create a diagnostic microarray that provides molecular diagnostic and prognostic information to patients with lymphoid malignancies. Dr. Staudt's research team also uses functional genomics, chemical genetics, and large-scale RNA interference, or RNAi, to identify new molecular targets for the treatment of lymphoid malignancies.
Dr. Grewal, head of the Chromosome Biology Section in CCR's Laboratory of Biochemistry and Molecular Biology, studies epigenetic control of gene expression and development. This work led him and his research team to discover a connection between natural RNAi and heterochromatin formation. In 2002, this discovery was selected as a "Breakthrough of the Year" by Science magazine.
NCI Cancer Classroom Webinar Series Wraps Up July 26
NCI's free, four-part webinar series, Cancer Classroom, concludes July 26 from 2:00 p.m. to 3:30 p.m. ET. The session, Clinical Trials 102, completes an overview of the clinical trials process, including recruitment and accrual challenges and available NCI resources.
The goal of the series has been to provide the educational guidance, tools, and resources necessary for early-career public health professionals or those new to the field of oncology to address cancer as a public health issue. Although the workshops are free, preregistration is required. To register or learn more, visit the NCI Cancer Classroom Series Web site.
If you missed the first three sessions, view them online:
Proposals Sought to Use Biospecimens from SELECT and PCPT
SWOG, formerly known as the Southwest Oncology Group, is making resources from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) and the Prostate Cancer Prevention Trial (PCPT), available to the wider research community for the development of novel translational research projects.
Together, SELECT and PCPT randomly assigned more than 53,000 men without prostate cancer to intervention or placebo, generating substantial clinical data related to the risk of developing prostate cancer, as well as corresponding biorepositories for molecular, epidemiologic, and other studies.
Proposals in four major categories will be considered: prostate cancer, cancers other than prostate, ancillary studies to SELECT and PCPT, and other health outcomes. Each proposal should include a concise plan of the research to be conducted during the proposed project period.
A proposal involving humans or animals may be approved, but funds will not be committed until appropriate institutional review board approval is received. Lists of previously approved studies and information about biorepositories and data elements are available at the SELECT and PCPT links above.
Researchers interested in using samples from SELECT or PCPT must submit a letter of intent to SWOG by 5:00 p.m. ET on September 1, 2011. Full applications are due by 5:00 p.m. ET on October 29, 2011.
SWOG will review proposals in January 2012 and send notifications in April 2012.